This article is more than 5 years old. Information may no longer be current.
RPS restructures AdenoPlus licensing agreement
Rapid Pathogen Screening has announced the restructuring of the North American licensing rights to the AdenoPlus test, as well as two diagnostic tests in development.
The AdenoPlus test is used to rapidly diagnose adenoviral conjunctivitis to primary and urgent care professionals in the U.S. and is already manufactured and marketed by RPS, according to a company press release.
In 2012, RPS and Nicox entered into a licensing agreement that granted Nicox access to RPS’s innovative diagnostic tests. However, AdenoPlus and future products will now be marketed to eye care U.S. eye care professionals and Canadian health care providers solely through RPS’s eye care team as of August 1.
The new agreement stipulates that Nicox will no longer contribute to development costs but may pay additional development milestones, up to a potential maximum of $525,000, related to approval of products outside North America, according to the press release.
“RPS built out a robust commercial sales organization targeting eye care professionals for the successful launch of InflammaDry. We view the AdenoPlus and InflammaDry tests as synergistic products that both aid in the in-office diagnosis of common diseases affecting the ocular surface,” Robert Sambursky, MD, CEO and president of RPS, said in the release. “Reacquiring the rights to AdenoPlus and future diagnostics in North America expands our eye care team’s product offerings, while maintaining a strong continued collaboration with Nicox outside North America.”
Rapid Pathogen Screening has announced the restructuring of the North American licensing rights to the AdenoPlus test, as well as two diagnostic tests in development.
The AdenoPlus test is used to rapidly diagnose adenoviral conjunctivitis to primary and urgent care professionals in the U.S. and is already manufactured and marketed by RPS, according to a company press release.
In 2012, RPS and Nicox entered into a licensing agreement that granted Nicox access to RPS’s innovative diagnostic tests. However, AdenoPlus and future products will now be marketed to eye care U.S. eye care professionals and Canadian health care providers solely through RPS’s eye care team as of August 1.
The new agreement stipulates that Nicox will no longer contribute to development costs but may pay additional development milestones, up to a potential maximum of $525,000, related to approval of products outside North America, according to the press release.
“RPS built out a robust commercial sales organization targeting eye care professionals for the successful launch of InflammaDry. We view the AdenoPlus and InflammaDry tests as synergistic products that both aid in the in-office diagnosis of common diseases affecting the ocular surface,” Robert Sambursky, MD, CEO and president of RPS, said in the release. “Reacquiring the rights to AdenoPlus and future diagnostics in North America expands our eye care team’s product offerings, while maintaining a strong continued collaboration with Nicox outside North America.”